Clinically aggressive metastasizing pleomorphic adenoma: Report of two cases
β Scribed by Jerzy Klijanienko; Adel K. El-Naggar; Vincent Servois; Joseph Rodriguez; Pierre Validire; Philippe Vielh
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 376 KB
- Volume
- 19
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
β¦ Synopsis
Background. It has been suggested that metastasizing pleomorphic adenomas may represent unrecognized malignancy.
Methods. The cytologic and clinical characteristics of two metastasizing pleomorphic adenomas diagnosed by fine-needle sampling are reported.
Results. Both showed malignant evolution: the primary tumors arose from the palate and the parotid salivary glands, respectively. Metastases occurred simultaneously with local recurrence in the first patient and after a second local recurrence in the second patient. Both patients were treated by surgery and radiotherapy but died of disseminated disease 8 and 4 years after initial diagnosis. No histologic evidence of malignancy was observed on cytology smears or histology sections in either case.
Conclusion. Clinically, our cases support the hypothesis that metastasizing pleomorphic adenomas represent unrecognized malignancy, because the biologic course of two tumors led to unequivocally lethal outcome.
π SIMILAR VOLUMES
Embryonal (metanephric) adenoma of the kidney, like Wilms' tumor, exhibits small monomorphic, blue cells arranged as vague, tubular rosettes. Unlike Wilms' tumor, which requires chemotherapy or multi-modality therapy for optimal management, the available evidence indicates that embryonal adenoma is
Anti-Hu-associated paraneoplastic sensory neuropathy (PSN) has been reported to be nonresponsive to immunotherapy or cancer therapy. We report 2 patients with anti-Hu-associated PSN who achieved sustained clinical improvement with early and aggressive immunotherapy 10-15 months before the diagnosis